Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: diabetes + 522 + web  Related to the article below (Last Update: 8/4/2008)

Business Bulletin Board for Aug. 3
Inside Bay Area, CA - Aug 3, 2008
510-522-0414. Haas Center for Executive Development ? "UC Berkeley Executive Session: Venture Capital," 8:30 am-10:30 pm Sept. 23. Haas School of Business, ...
Your weekly planner
Bucyrus Telegraph Forum,  United States - Jul 22, 2008
Diabetes support group -- 7-8 pm, Ohio Mutual room of Bucyrus Community Hospital. Speakers vary. Coffee and water are served. BHS Class 1941 -- luncheon ...
Your weekly planner
Bucyrus Telegraph Forum,  United States - Jul 26, 2008
Call Carolyn Irmscher at 740-522-2455 for details. Childbirth classes -- 7-9 pm, Galion Community Hospital. Make reservations by calling 419-468-0910. ...
Your weekly planner
Bucyrus Telegraph Forum,  United States - Jul 12, 2008
Call 419-522-0211 for details. Conservation and Agriculture Tour -- 3-5 pm, bus leaves from Crawford County Fairgrounds to go to Pfeifer Dairy Farm. ...
Your weekly planner
Bucyrus Telegraph Forum,  United States - Jul 14, 2008
Diabetes support group -- 7-8 pm, Ohio Mutual room of Bucyrus Community Hospital. Speakers vary. Coffee and water are served. ...
Your weekly planner
Bucyrus Telegraph Forum,  United States - Jul 17, 2008
Call Carolyn Irmscher at 740-522-2455 for details. Childbirth classes -- 7-9 pm, Galion Community Hospital. Make reservations by calling 419-468-0910. ...
Your weekly planner
Bucyrus Telegraph Forum,  United States - Jul 18, 2008
Call 419-522-0211 for details. Singing with deejay Larry -- Sharpies Crossing, 642 Woodlawn Ave. Bucyrus City Planning Commission -- 10 am, council chambers ...
Parkway regional calendar
Wicked Local Roslindale, MA - Jul 16, 2008
For more information, call Deborah at Boston Money Management at 617 522-6700 or email dgrose@ethocare.org. Child Assault Prevention program? Volunteers ...
Regional calendar
Wicked Local Roslindale, MA - Jul 10, 2008
For more information, call Deborah at Boston Money Management at 617 522-6700 or email dgrose@ethocare.org. Child Assault Prevention program? Volunteers ...

In order to show you the most relevant results, we have omitted some entries very similar to the 9 already displayed.
If you like, you can repeat the search with the omitted results included.

Source: Google News

Internet Marketing of Herbal Products -
CA Morris, J Avorn - JAMA, 2003 - Am Med Assoc
... Dang Shen is given for breast cancer, asthma, diabetes, heart palpitations, memory
or appetite loss and insomnia ... Herbal cancer cures on the Web. ... 2002;34:522-527 ...

… , flow-mediated vasodilation in elderly individuals without and with diabetes: Further evidence for … -
CD Stehouwer, RM Henry, JM Dekker, G Nijpels, RJ … - Kidney Int Suppl, 2004 - nature.com
Full text access provided to Googlebot Access by Web Services. Kidney International
homepage ... The Hoorn Study. Diabetes Care 2004 27: 522?529, | PubMed ...

Alcohol Consumption and Risk of Type 2 Diabetes Mellitus Among US Male Physicians -
UA Ajani, CH Hennekens, A Spelsberg, JAE Manson - Archives of Internal Medicine, 2000 - Am Med Assoc
... this message because your Web browser does not support basic Web standards. ... Alcohol
Consumption and Risk of Type 2 Diabetes Mellitus Among US Male Physicians ...

Application of isotope-selective nondispersive infrared spectrometry (IRIS) for evaluation of [13C] … -
P Schadewaldt, B Schommartz, G Wienrich, H … - Clinical Chemistry, 1997 - Am Assoc Clin Chem
... 1997;43:518-522.) ? 1997 American Association for Clinical Chemistry ... 1 Diabetes
Forschungsinstitut, 2 Nuklearmedizinische Klinik, and 3 Kinderklinik, Heinrich ...

Main Risk Factors for Nephropathy in Type 2 Diabetes Mellitus Are Plasma Cholesterol Levels, Mean … -
M Ravid, D Brosh, D Ravid-Safran, Z Levy, R … - Archives of Internal Medicine, 1998 - Am Med Assoc
... this message because your Web browser does not support basic Web standards ... Main Risk
Factors for Nephropathy in Type 2 Diabetes Mellitus Are Plasma Cholesterol ...

Tests of Glycemia in Diabetes -
DE Goldstein, RR Little, RA Lorenz, JI Malone, D … - Diabetes Care, 2004 - Am Diabetes Assoc
... (120) and on the National Glycohemoglobin Standardization Program (NGSP) Web site
at ... The DCCT set the stage for establishing specific diabetes treatment goals ...

[PDF] Diabetes Epidemic -
D Epidemic - docs.ksu.edu.sa
... Web based 10,000 Step Programs ... DM Prevention Trials Finnish Diabetes Prevention Study
Diabetes Prevention Program 522 overweight individuals with IGT ...
-

Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis … -
H Kahles, E Ramos-Lopez, B Lange, O Zwermann, M … - European Journal of Endocrinology, 2005 - eje.org
... J. Timsit, and C. Julier PTPN22 R620W Functional Variant in Type 1 Diabetes and
Autoimmunity Related Traits Diabetes, February 1, 2007; 56(2): 522 - 526. ...

… patients with coronary artery disease across Europe The Euro Heart Survey on diabetes and the heart -
M Bartnik, L Ryden, R Ferrari, K Malmberg, K … - European Heart Journal, 2004 - Eur Soc Cardiology
... collected by means of a web based electronic ... angina pectoris Circulation
1976;54:522-523.[ISI ... Definition, diagnosis and classification of diabetes mellitus ...

Type 1 diabetes: new perspectives on disease pathogenesis and treatment -
MA Atkinson, GS Eisenbarth - The Lancet, 2001 - Elsevier
... innovations for patients with established type 1 diabetes. Improved home devices
and monitors. Glucose. Fructosamine. HbA 1c. Data download to physician via web ...

Source: Google Scholar
 
 

Type 2 diabetes and nephropathy, Ruboxistaurin shows favorable effects

 
 
A one-year pilot study examined the effect of Ruboxistaurin in patients with type 2 diabetes and diabetic nephropathy.

Data showed that in patients being treated with angiotensin converting enzyme inhibitors ( ACE inhibitors ), angiotensin receptor blockers ( ARBs ), or both, Ruboxistaurin significantly reduced albuminuria, an indicator of diabetic kidney damage, by 24%, compared to a non-significant 9% reduction in patients taking placebo.

" The results from this study are very encouraging for people with type 2 diabetes who suffer from diabetic nephropathy," said Katherine R. Tuttle, lead investigator of the study, from Providence Medical Research Center and The Heart Institute of Spokane. " The significant improvement of albuminuria with Ruboxistaurin in patients already treated with ACE inhibitors or ARBs suggests that the drug may be helpful in further slowing the progression of kidney disease."

Albuminuria is considered the first clinical indication of diabetic nephropathy. Diabetic nephropathy is a diabetic microvascular complication ( DMC ) caused by damage to the small blood vessels in the kidneys. It occurs in approximately 40 percent of people with diabetes and is the leading cause of kidney failure in the United States and the developed world.

Reductions in albuminuria with Ruboxistaurin were seen after one month of treatment and remained consistent throughout the study. In addition, patients taking placebo experienced a significant loss of kidney function after 1 year, however kidney function was stable in patients treated with Ruboxistaurin.

In this multicenter, randomized, double-blinded, parallel placebo- controlled trial, 123 subjects were randomized at 17 clinical sites in the United States to receive either 32 mg/day of Ruboxistaurin or placebo. Participants were required to be taking stable doses of either ACE inhibitors, ARBs, or both, for 6 months prior to the study and these agents were continued throughout the trial. Baseline characteristics did not differ significantly between treatment groups. Blood glucose and blood pressure control was similar at the beginning and throughout the study.

Analyses of adverse events in this trial revealed no significant differences between the Ruboxistaurin ( 15 reported ) and placebo ( 9 reported ) groups, except in the placebo group for episodes of hypertension requiring intervention ( 8% of placebo participants had an episode of hypertension requiring intervention compared with 0% in Ruboxistaurin treated group ).
The most frequently reported adverse event in this clinical trial was hypertension. Three Ruboxistaurin-treated participants withdrew due to adverse events ( decreased libido, impaired mental status, and metastatic cancer ).
Based upon the results of this pilot study, Ruboxistaurin was well tolerated; but the small sample size and limited duration of follow-up precludes a firm conclusion about safety.

Ruboxistaurin is a specific protein kinase C beta ( PKC b ) inhibitor, the first of a new class of compounds being investigated for the treatment of diabetic peripheral neuropathy, diabetic retinopathy and diabetic nephropathy, the three major diabetic microvascular complications ( DMCs ) associated with type 1 and type 2 diabetes. Metabolic factors associated with diabetes often lead to damage to the small blood vessels in the nerves, eyes and kidneys, ultimately leading to DMCs.

Pre-clinical data show that Ruboxistaurin is a specific inhibitor of PKC b.
PKC b is an enzyme that has been implicated in the underlying process of microvascular damage caused by diabetes.

Source: American Diabetes Association ( ADA ) 65th Annual Scientific Sessions, 2005
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page